Hypocretin (orexin) loss in Parkinson's disease

Brain

Volumn 130, Issue 6, 2007, Pages 1577-1585

  Fronczek, Rolf ^a,b   Overeem, Sebastiaan ^a,c   Lee, Sandy Y Y ^b   Hegeman, Ingrid M ^a   Van Pelt, Johannes ^a   Van Duinen, Sjoerd G ^a   Lammers, Gert Jan ^a   Swaab, Dick F ^b  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^b NETHERLANDS INSTITUTE FOR NEUROSCIENCE   (Netherlands)

^c RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Hypocretin; Hypothalamus; Narcolepsy; Orexin; Parkinson's disease; Sleep

Indexed keywords

OREXIN; NEUROPEPTIDE; OREXINS; SIGNAL PEPTIDE; UNCLASSIFIED DRUG;

ARTICLE; AUTOPSY; BRAIN NERVE CELL; CEREBROSPINAL FLUID; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; HYPOTHALAMUS; IMAGE ANALYSIS; IMMUNOCYTOCHEMISTRY; LEWY BODY; MALE; NEUROTRANSMISSION; PARKINSON DISEASE; PREFRONTAL CORTEX; PRIORITY JOURNAL; RADIOIMMUNOASSAY; AGED; CELL COUNT; CHEMISTRY; ENZYME IMMUNOASSAY; METABOLISM; MIDDLE AGED; NERVE CELL; PATHOLOGY;

AGED; AGED, 80 AND OVER; CELL COUNT; FEMALE; HUMANS; HYPOTHALAMUS; IMMUNOENZYME TECHNIQUES; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; LEWY BODIES; MALE; MIDDLE AGED; NEURONS; NEUROPEPTIDES; PARKINSON DISEASE; PREFRONTAL CORTEX;

EID: 34250841699     PISSN: 00068950     EISSN: 14602156     Source Type: Journal    
DOI: 10.1093/brain/awm090     Document Type: Article

References (36)

1. Arnulf I. Excessive daytime sleepiness in parkinsonism. Sleep Med Rev 2005; 9: 185-200.
2. Arnulf I, Bonnet AM, Damier P, Bejjani BP, Seilhean D, Derenne JP, et al. Hallucinations, REM sleep, and Parkinson's disease: a medical hypothesis. Neurology 2000; 55: 281-8.
3. Arnulf I, Konofal E, Merino-Andreu M, Houeto JL, Mesnage V, Welter ML, et al. Parkinson's disease and sleepiness: an integral part of PD. Neurology 2002; 58: 1019-24.
4. Bao AM, Hestiantoro A, Van Someren EJW, Swaab DF, Zhou JN. Colocalization of corticotropin-releasing hormone and oestrogen receptor-α in the paraventricular nucleus of the hypothalamus in mood disorders. Brain 2005; 128: 1301-13.
5. Baumann C, Ferini-Strambi L, Waldvogel D, Werth E, Bassetti CL. Parkinsonism with excessive daytime sleepiness-a narcolepsy-like disorder? J Neurol 2005; 252: 139-45.
6. Baumann CR, Stocker R, Imhof HG, et al. Hypocretin-1 (orexin A) deficiency in acute traumatic brain injury. Neurology 2005; 65: 147-9.
7. Braak H, Braak E, Bohl J. Staging of Alzheimer-related cortical destruction. Eur Neurol 1993; 33: 403-8.
8. Braak H, Ghebremedhin E, Rub U, Bratzke H, Del Tredici K. Stages in the development of Parkinson's disease-related pathology. Cell Tissue Res 2004; 318: 121-34.
9. Brodsky MA, Godbold J, Roth T, Olanow CW. Sleepiness in Parkinson's disease: a controlled study. Mov Disord 2003; 18: 668-72.
10. Chaudhuri KR, Healy DG, Schapira AH. Non-motor symptoms of Parkinson's disease: diagnosis and management. Lancet Neurol 2006; 5: 235-45.
11. Chen CT, Dun SL, Kwok EH, Dun NJ, Chang JK. Orexin A-like immunoreactivity in the rat brain. Neurosci Lett 1999; 260: 161-4.
12. Chen L, Thakkar MM, Winston S, Bolortuya Y, Basheer R, McCarley RW. REM sleep changes in rats induced by siRNA-mediated orexin knockdown. Eur J Neurosci 2006; 24: 2039-48.
13. Chung WC, De Vries GJ, Swaab DF. Sexual differentiation of the bed nucleus of the stria terminalis in humans may extend into adulthood. J Neurosci 2002; 22: 1027-33.
14. Drouot X, Moutereau S, Nguyen JP, Lefaucheur JP, Creange A, Remy P, et al. Low levels of ventricular CSF orexin/hypocretin in advanced PD. Neurology 2003; 61: 540-3.
15. Ebrahim IO, Sharief MK, de Lacy S, Semra YK, Howard RS, Kopelman MD, et al. Hypocretin (orexin) deficiency in narcolepsy and primary hypersomnia. J Neurol Neurosurg Psychiatry 2003; 74: 127-30.
16. Fronczek R, Lammers GJ, Balesar R, Unmehopa UA, Swaab DF. The number of hypothalamic hypocretin (orexin) neurons is not affected in Prader-Willi syndrome. J Clin Endocrinol Metab 2005; 90: 5466-70.
17. Gagnon JF. REM sleep behavior disorder and REM sleep without atonia in Parkinson's disease. Neurology 2002; 59: 585-9.
18. Gerashchenko D, Murillo-Rodriguez E, Lin L, Xu M, Hallett L, Nishino S, et al. Relationship between CSF hypocretin levels and hypocretin neuronal loss. Exp Neurol 2003; 184: 1010-6.
19. Goldstone AP, Unmehopa UA, Bloom SR, Swaab DF. Hypothalamic NPY and agouti-related protein are increased in human illness but not in Prader-Willi syndrome and other obese subjects. J Clin Endocrinol Metab 2002; 87: 927-37.
20. Hobson DE, Lang AE, Martin WR, Razmy A, Rivest J, Fleming J. Excessive daytime sleepiness and sudden-onset sleep in Parkinson disease: a survey by the Canadian Movement Disorders Group. Jama 2002; 287: 455-63.
21. International Classification of Sleep Disorders - Second Edition. Rochester (MN): American Academy of Sleep Medicine, 2005.
22. Jellinger KA. The pathology of Parkinson's disease. Adv Neurol 2001; 86: 55-72.
23. Jones RL. Split nucleoli as a source of error in nerve cell counts. Stain Technol 1937; 12: 91-5.
24. Langston JW, Forno LS. The hypothalamus in Parkinson disease. Ann Neurol 1978; 3: 129-33.
25. Mason DY, Sammons R. Alkaline phosphatase and peroxidase for double immunoenzymatic labelling of cellular constituents. J Clin Path 1978; 31: 454-60.
26. Mignot E, Lammers GJ, Ripley B, Okun M, Nevsimalova S, Overeem S, et al. The role of cerebrospinal fluid hypocretin measurement in the diagnosis of narcolepsy and other hypersomnias. Arch Neurol 2002; 59: 1553-62.
27. Overeem S, Mignot E, van Dijk JG, Lammers GJ. Narcolepsy: clinical features, new pathophysiologic insights, and future perspectives. J Clin Neurophysiol 2001; 18: 78-105.
28. Overeem S, van Hilten JJ, Ripley B, Mignot E, Nishino S, Lammers GJ. Normal hypocretin-1 levels in Parkinson's disease patients with excessive daytime sleepiness. Neurology 2002; 58: 498-9.
29. Panayotacopoulou MT, Raadsheer FC, Swaab DF. Colocalization of tyrosine hydroxylase with oxytocin or vasopressin in neurons of the human paraventricular and supraoptic nucleus. Brain Res Dev Brain Res 1994; 83: 59-66.
30. Peyron C, Faraco J, Rogers W, Ripley B, Overeem S, Charnay Y, et al. A mutation in a case of early onset narcolepsy and a generalized absence of hypocretin peptides in human narcoleptic brains. Nat Med 2000; 6: 991-7.
31. Peyron C, Tighe DK, van den Pol AN, de Lecea L, Heller HC, Sutcliffe JG, et al. Neurons containing hypocretin (orexin) project to multiple neuronal systems. J Neurosci 1998; 18: 9996-10015.
32. Rye DB, Jankovic J. The two faces of Eve: dopamine's modulation of wakefulness and sleep. Neurology 2004; 63: S2-7.
33. Ripley B, Overeem S, Fujiki N, Nevsimalova S, Uchino M, Yesavage J, et al. CSF hypocretin/orexin levels in narcolepsy and other neurological conditions. Neurology 2001; 57: 2253-8.
34. Siegel JM. Hypocretin (orexin): role in normal behavior and neuropathology. Annu Rev Psychol 2004; 55: 125-48.
35. Thannickal TC, Moore RY, Nienhuis R, Ramanathan L, Gulyani S, Aldrich M, et al. Reduced number of hypocretin neurons in human narcolepsy. Neuron 2000; 27: 469-74.
36. Van de Nes JA, Kamphorst W, Ravid R, Swaab DF. Comparison of beta-protein/A4 deposits and Alz-50-stained cytoskeletal changes in the hypothalamus and adjoining areas of Alzheimer's disease patients: amorphic plaques and cytoskeletal changes occur independently. Acta Neuropathol (Berl) 1998; 96: 129-38.